Development of a simple and rapid method to measure the free fraction of tacrolimus in plasma using ultrafiltration and LC-MS/MS

Therapeutic Drug Monitoring

Volumn 38, Issue 6, 2016, Pages 722-727

  Stienstra, Nicolaas A ^a   Sikma, Maaike A ^b   Van Dapperen, Anouk L ^a   De Lange, Dylan W ^b   Van Maarseveen, Erik M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

LC MS MS; Tacrolimus; Transplant; Ultrafiltration; Unbound concentration

Indexed keywords

TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BLOOD ANALYSIS; DRUG BLOOD LEVEL; DRUG DETERMINATION; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; PRECIPITATION; PRIORITY JOURNAL; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; ULTRAFILTRATION; VALIDATION STUDY; BLOOD; CHEMISTRY; DRUG MONITORING; LIMIT OF DETECTION; PLASMA; PROCEDURES; REPRODUCIBILITY;

CHROMATOGRAPHY, LIQUID; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIMIT OF DETECTION; PLASMA; REPRODUCIBILITY OF RESULTS; SOLID PHASE EXTRACTION; TACROLIMUS; TANDEM MASS SPECTROMETRY; ULTRAFILTRATION;

EID: 84994157704     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000351     Document Type: Article

References (28)

1. Guethoff S, Meiser BM, Groetzner J, et al. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation. Transplantation. 2013;95:629-634.
2. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324: 667-674.
3. Grimm M, Rinaldi M, Yonan NA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients-a large European trial. Am J Transplant. 2006;6:1387-1397.
4. Sikma MA, van Maarseveen EM, van de Graaf EA, et al. Pharmacokinetics and toxicity of tacrolimus early after heart and lung transplantation. Am J Transplant. 2015;15:2301-2313.
5. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation. 1996;62:920-926.
6. Schwartz M, Holst B, Facklam D, et al. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization. Transplant Proc. 1995;27:1107.
7. Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant. 2001;16:1905-1909.
8. Takahara S, Kokado Y, Kameoka H, et al. Monitoring of FK 506 blood levels in kidney transplant recipients. Transplant Proc. 1994; 26:2106-2108.
9. Winkler M, Wonigeit K, Undre N, et al. Comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring. Transplant Proc. 1995;27:822-825.
10. Hebert MF, Zheng S, Hays K, et al. Interpreting tacrolimus concentrations during pregnancy and postpartum. Transplantation. 2013;95: 908-915.
11. Yoshida EM, Marotta PJ, Greig PD, et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl. 2005;11:1064-1072.
12. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther. 1995;57: 281-290.
13. Warty VS, Zuckerman S, Venkataramanan R, et al. Tacrolimus analysis: a comparison of different methods and matrices. Ther Drug Monit. 1995; 17:159-167.
14. Warty VS, Zuckerman S, Venkataramanan R, et al. FK506 measurement: comparison of different analytical methods. Ther Drug Monit. 1993;15: 204-208.
15. Iwasaki K, Miyazaki Y, Teramura Y, et al. Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acid. Res Commun Mol Pathol Pharmacol. 1996;94:251-257.
16. Nagase K, Iwasaki K, Nozaki K, et al. Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J Pharm Pharmacol. 1994;46:113-117.
17. Weiss HM, Fresneau M, Moenius T, et al. Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Drug Metab Dispos. 2008;36:1812-1818.
18. Zahir H, McCaughan G, Gleeson M, et al. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol. 2004;57:298-309.
19. Zahir H, McCaughan G, Gleeson M, et al. Changes in tacrolimus distribution in blood and plasma protein binding following liver transplantation. Ther Drug Monit. 2004;26:506-515.
20. Zahir H, Nand RA, Brown KF, et al. Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J Pharmacol Toxicol Methods. 2001;46:27-35.
21. Zheng S, Easterling TR, Umans JG, et al. Pharmacokinetics of tacrolimus during pregnancy. Ther Drug Monit. 2012;34:660-670.
22. Lefaucheur C, Nochy D, Amrein C, et al. Renal histopathological lesions after lung transplantation in patients with cystic fibrosis. Am J Transplant. 2008;8:1901-1910.
23. Machida M, Takahara S, Ishibashi M, et al. Effect of temperature and hematocrit on plasma concentration of FK 506. Transplant Proc. 1991; 23:2753-2754.
24. Annesley TM, Clayton L. Simple extraction protocol for analysis of immunosuppressant drugs in whole blood. Clin Chem. 2004;50: 1845-1848.
25. Koster RA, Dijkers EC, Uges DR. Robust, high-throughput LC-MS/MS method for therapeutic drug monitoring of cyclosporine, tacrolimus, everolimus, and sirolimus in whole blood. Ther Drug Monit. 2009;31: 116-125.
26. FDA. Bioanalytical Method Validation [web site]. 2001. Available at: http:// www. fda. gov/downloads/Drugs/Guidances/ucm070107. pdf. Accessed 2015.
27. Howard ML, Hill JJ, Galluppi GR, et al. Plasma protein binding in drug discovery and development. Comb Chem High Throughput Screen. 2010;13:170-187.
28. Lee KJ, Mower R, Hollenbeck T, et al. Modulation of nonspecific binding in ultrafiltration protein binding studies. Pharm Res. 2003; 20:1015-1021.